Almost 10 years have passed since its first FDA approval and Regeneron’s macular degeneration injection Eylea continues to pile up sales to the tune of about $5 billion per year, or more than half of Regeneron’s annual revenues.

Those billions are not expected to go anywhere anytime soon thanks to competition, even as Novartis subsidiary Sandoz announced Monday that it’s beginning a Phase III trial for an Eylea biosimilar in 460 patients across 20 countries.

Despite its long-reaching effects in global markets, the Covid-19 pandemic is not expected to broadly impact global sales on medicines in the near-term future, according to a new report from IQVIA.

Over the next five or so years, through 2025, global spending will grow at an estimated 3% to 6% rate annually and reach $1.6 trillion in sales. Notably, that figure does not include an additional $157 billion expected to be spent on Covid-19 vaccines, which will mostly come from now through the end of 2022.

When it submitted a supplemental Biologic License Application to the FDA, Biogen hoped they could offer patients with multiple sclerosis an easier way of receiving and administering their therapy Tysabri. But Thursday, it received a CRL denying the approval of its filing, and it isn’t offering any explanation behind it.

The company turned down a request for further explanation from Endpoints News Friday.

Two months after Bristol Myers Squibb announced Opdivo nearly doubled the average length of time patients with a common bladder cancer lived without disease recurrence, regulators have said they’ll give the PD-1 blockbuster an expedited look.

The FDA has granted priority review to Opdivo as an adjuvant treatment in muscle-invasive urothelial cancer, Bristol Myers said on Friday, marking the latest win in the pharma’s bid to outshine Merck’s superstar I/O Keytruda. The agency tapped Sept. 3 for a PDUFA date.

For the first earnings report of the year, AstraZeneca invented a new metric: the profit they’d have if you didn’t count their Covid-19 vaccine costs.

When AstraZeneca announced last year that they would develop Oxford’s Covid-19 candidate, they said they would sell it on a not-for-profit basis during the pandemic. The terms fulfilled the vaccine’s academic inventors’ desire to see their shot deployed cheaply around the world, while also allowing the drugmaker to do some good and, potentially, secure a massive PR coup.

AbbVie CEO Richard Gonzalez will be in the hot seat on May 18, again defending the company’s mammoth blockbuster drug Humira before the House Oversight Committee as competition for the world’s best-selling drug isn’t likely to hit American shores for about two years.

Oversight Committee Chairwoman Carolyn Maloney (D-NY) has been zeroing in on AbbVie for months now, even threatening to issue a subpoena last September for documents as part of her committee’s ongoing investigation into drug pricing practices.